AI and Cancer Research ── Gastric ── 2026-11-19
Gastric cancer: treatment, trials and AI
- Abstract
RATIONALE AND OBJECTIVES: To develop and validate a computed tomography-based model integrating multichannel deep learning and radiomics for predicting pathologic significant response (PSR) to neoadjuvant chemoimmunotherapy (NACI) in locally advanced gastric cancer (LAGC), and to assess whether the model specifically captures immunotherapy-related phenotypes by testing it on a chemotherapy-alone cohort. MATERIALS AND METHODS: This multicenter study included 455 patients with LAGC: 411 receiving NACI (split into training, internal validation, and external test set 1) and 44 receiving chemotherapy alone (test set 2). From three-dimensional (3D) segmentations, the largest axial, coronal, and sagittal slices were stacked as three-channel input for a pretrained ResNet50 to extract deep features; radiomic features were extracted from the 3D volume. Features were fused, reduced by the least absolute shrinkage and selection operator, and modeled with a support vector machine to construct a deep learning radiomics (DLR) signature. A combined model further incorporated mismatch repair status, programmed death-ligand 1 combined positive score, and tumor grade. Model performance was evaluated by area under the curve (AUC), calibration, and decision curve analysis, with SHAP for interpretability. RESULTS: The multichannel model outperformed single-plane models (AUCs: 0.783, 0.749, 0.706). The DLR model achieved the highest AUCs (0.827, 0.802, 0.776), surpassing radiomics-only (0.756, 0.712, 0.691) and multichannel deep models. Critically, its AUC dropped to 0.597 in the chemotherapy-alone cohort. SHAP provided global and individual feature attributions. CONCLUSION: The multichannel DLR model accurately predicts PSR to NACI in LAGC. The substantial performance decline in the chemotherapy-alone cohort suggests that the captured imaging phenotypes may be more closely associated with immunotherapy-related response, rather than with general chemosensitivity, potentially offering a noninvasive, interpretable tool for pretreatment stratification.
Journal IF-equivalent: 3.5 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)Reference: Ran C, Wang C, Chu G, Kong D. Multichannel Deep Learning Radiomics for Predicting Chemoimmunotherapy Response in Gastric Cancer: Multicenter Validation and Chemotherapy-alone Specificity Assessment. Acad Radiol. 2026 Nov [Epub ahead of print]. doi:10.1016/j.acra.2026.10.035. PMID: 43039808.Checked: Abstract only